World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
34479
World Ranking
11656
National Ranking
5978

Overview

Nizar M. Tannir is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans various domains within medicine, biochemistry, genetics, and molecular biology, with particular emphasis on pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and surgery.

Their scientific contributions have covered a broad range of topics, notably in renal cell carcinoma treatment, renal and related cancers, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, bladder and urothelial cancer treatments, pancreatic and hepatic oncology research, and ferroptosis and cancer prognosis.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Cancer Research
  • The Oncologist
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts

Co-authors who have collaborated extensively with Nizar M. Tannir include:

  • Pavlos Msaouel
  • Amishi Y. Shah
  • Matthew T. Campbell
  • Jianjun Gao
  • Eric Jonasch

Among recent scientific papers authored or co-authored by Nizar M. Tannir are:

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, 2020, Cancer
  • Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma, 2022, Cancer
  • Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02), 2020, Cancer Discovery
  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial, 2020, Journal for ImmunoTherapy of Cancer

Best Publications

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

    Ana M. Aparicio;Andrea L. Harzstark;Paul G. Corn;Sijin Wen;Sijin Wen

  • Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer

    Sriram Yennurajalingam;Susan Frisbee-Hume;J. Lynn Palmer;Marvin O. Delgado-Guay

  • Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

    Lijun Zhou;Xian-De Liu;Mianen Sun;Xuesong Zhang

  • Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

    Michael B. Atkins;Nizar M. Tannir

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.

    Aarif Y. Khakoo;Christos M. Kassiotis;Nizar M Tannir;Juan Carlos Plana

  • Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

    Omar Mamlouk;Umut Selamet;Shana Machado;Maen Abdelrahim

  • Renal cell carcinoma: diagnosis, staging, and surveillance.

    Chaan S. Ng;Christopher G. Wood;Paul M. Silverman;Nizar M. Tannir

  • Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy

    Stephen H. Culp;Nizar M. Tannir;E. Jason Abel;Vitaly Margulis

  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

    Robert J. Motzer;Bernard Escudier;Saby George;Hans J. Hammers

  • Patient survival after surgery for osseous metastases from renal cell carcinoma.

    Patrick P. Lin;Attiqa N. Mirza;Valerae O. Lewis;Christopher P. Cannon

  • Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling

    Lorenzo Cohen;Steven W. Cole;Anil K. Sood;Sarah Prinsloo

  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Osvaldo Arén Frontera

  • Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq

    Joseph D. Khoury;Nizar M. Tannir;Michelle D. Williams;Yunxin Chen

Frequent Co-Authors

Eric Jonasch
Eric Jonasch The University of Texas MD Anderson Cancer Center
Christopher G. Wood
Christopher G. Wood The University of Texas MD Anderson Cancer Center
Surena F. Matin
Surena F. Matin The University of Texas MD Anderson Cancer Center
Pheroze Tamboli
Pheroze Tamboli The University of Texas MD Anderson Cancer Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Thomas Powles
Thomas Powles Queen Mary University of London
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Xiaoping Su
Xiaoping Su The University of Texas MD Anderson Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in pursuing a medical career but aren't committed to a traditional MD path, there are several rewarding alternatives available through online study. Many students are now considering health administration roles, which are in high demand as healthcare systems grow more complex. For those wanting to lead in healthcare organizations, exploring the best online mha programs can open doors to managerial and executive roles.

Cost is often a major concern. Learners can find the cheapest online master degree in healthcare administration to keep their studies affordable without sacrificing quality or accreditation.

For nurses aiming for the top clinical roles, affordable doctoral programs are available. The most affordable dnp programs prepare practitioners for advanced practice and leadership positions in healthcare settings.

Aspiring pharmacists can also benefit from flexible online options. Consider enrolling in accredited online pharmacy programs to kickstart your pharmaceutical career and respond to growing community health needs.

Best Scientists Citing Nizar M. Tannir

Trending Scientists